Cytek Biosciences, Inc. Operating Income Loss

Quick Answer

Cytek Biosciences, Inc. reported Operating Income Loss of -$40.38 million for the year ending 2025.

  • Cytek Biosciences, Inc. showed a decrease of -96.8% in Operating Income Loss from 2024 to 2025.
  • This data is from Cytek Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), Cytek Biosciences, Inc.'s Operating Income Loss has declined by 395.7%.
  • Historical annual values: Fiscal year 2025: -$40.38 million | Fiscal year 2024: -$20.52 million | Fiscal year 2023: -$27.85 million | Fiscal year 2022: -$1.80 million | Fiscal year 2021: $9.16 million | Fiscal year 2020: $13.66 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: